vs

Side-by-side financial comparison of NI Holdings, Inc. (NODK) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $61.0M, roughly 1.2× NI Holdings, Inc.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs -17.5%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs -9.5%).

NI Holdings, Inc. is a United States-based insurance holding company that primarily provides property and casualty insurance products. Its core offerings include personal auto insurance, homeowners insurance, and small commercial insurance, serving individual consumers and small business clients across multiple U.S. states.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

NODK vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.2× larger
PBYI
$75.5M
$61.0M
NODK
Growing faster (revenue YoY)
PBYI
PBYI
+45.2% gap
PBYI
27.7%
-17.5%
NODK
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
-9.5%
NODK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NODK
NODK
PBYI
PBYI
Revenue
$61.0M
$75.5M
Net Profit
$-3.2M
Gross Margin
30.8%
69.3%
Operating Margin
-4.7%
22.7%
Net Margin
-5.2%
Revenue YoY
-17.5%
27.7%
Net Profit YoY
-132.0%
EPS (diluted)
$-0.16
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NODK
NODK
PBYI
PBYI
Q4 25
$61.0M
$75.5M
Q3 25
$76.6M
$54.5M
Q2 25
$76.1M
$52.4M
Q1 25
$71.4M
$46.0M
Q4 24
$73.9M
$59.1M
Q3 24
$89.0M
$80.5M
Q2 24
$87.8M
$47.1M
Q1 24
$74.5M
$43.8M
Net Profit
NODK
NODK
PBYI
PBYI
Q4 25
$-3.2M
Q3 25
$-1.7M
$8.8M
Q2 25
$-12.1M
$5.9M
Q1 25
$6.5M
$3.0M
Q4 24
$9.8M
Q3 24
$-2.7M
$20.3M
Q2 24
$-19.6M
$-4.5M
Q1 24
$6.4M
$-4.8M
Gross Margin
NODK
NODK
PBYI
PBYI
Q4 25
30.8%
69.3%
Q3 25
20.5%
77.7%
Q2 25
8.4%
76.5%
Q1 25
40.6%
77.1%
Q4 24
52.7%
76.4%
Q3 24
20.4%
63.9%
Q2 24
18.0%
77.4%
Q1 24
39.9%
75.5%
Operating Margin
NODK
NODK
PBYI
PBYI
Q4 25
-4.7%
22.7%
Q3 25
-2.4%
17.6%
Q2 25
-20.1%
12.7%
Q1 25
10.8%
8.7%
Q4 24
18.7%
22.6%
Q3 24
-3.9%
27.4%
Q2 24
-10.3%
-4.6%
Q1 24
11.9%
-5.3%
Net Margin
NODK
NODK
PBYI
PBYI
Q4 25
-5.2%
Q3 25
-2.2%
16.2%
Q2 25
-15.8%
11.2%
Q1 25
9.0%
6.5%
Q4 24
13.3%
Q3 24
-3.0%
25.2%
Q2 24
-22.3%
-9.6%
Q1 24
8.6%
-11.0%
EPS (diluted)
NODK
NODK
PBYI
PBYI
Q4 25
$-0.16
$0.26
Q3 25
$-0.08
$0.17
Q2 25
$-0.57
$0.12
Q1 25
$0.31
$0.06
Q4 24
$0.48
$0.40
Q3 24
$-0.13
$0.41
Q2 24
$-0.94
$-0.09
Q1 24
$0.30
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NODK
NODK
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$52.2M
$97.5M
Total DebtLower is stronger
$2.4M
$22.7M
Stockholders' EquityBook value
$240.3M
$130.3M
Total Assets
$506.0M
$216.3M
Debt / EquityLower = less leverage
0.01×
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NODK
NODK
PBYI
PBYI
Q4 25
$52.2M
$97.5M
Q3 25
$24.7M
$94.4M
Q2 25
$56.8M
$96.0M
Q1 25
$57.2M
$93.2M
Q4 24
$51.4M
$101.0M
Q3 24
$39.1M
$96.7M
Q2 24
$51.4M
$96.8M
Q1 24
$68.5M
$107.2M
Total Debt
NODK
NODK
PBYI
PBYI
Q4 25
$2.4M
$22.7M
Q3 25
$2.4M
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$2.4M
$68.0M
Q3 24
$2.4M
$79.3M
Q2 24
$2.4M
$90.7M
Q1 24
$2.4M
$102.0M
Stockholders' Equity
NODK
NODK
PBYI
PBYI
Q4 25
$240.3M
$130.3M
Q3 25
$243.8M
$115.3M
Q2 25
$243.3M
$104.7M
Q1 25
$254.0M
$97.1M
Q4 24
$244.6M
$92.1M
Q3 24
$241.4M
$71.1M
Q2 24
$236.1M
$48.5M
Q1 24
$255.8M
$51.0M
Total Assets
NODK
NODK
PBYI
PBYI
Q4 25
$506.0M
$216.3M
Q3 25
$543.8M
$202.9M
Q2 25
$620.1M
$194.9M
Q1 25
$525.4M
$196.2M
Q4 24
$526.5M
$213.3M
Q3 24
$559.9M
$220.7M
Q2 24
$571.0M
$205.0M
Q1 24
$674.5M
$214.1M
Debt / Equity
NODK
NODK
PBYI
PBYI
Q4 25
0.01×
0.17×
Q3 25
0.01×
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.01×
0.74×
Q3 24
0.01×
1.12×
Q2 24
0.01×
1.87×
Q1 24
0.01×
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NODK
NODK
PBYI
PBYI
Operating Cash FlowLast quarter
$13.2M
$14.4M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.0%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NODK
NODK
PBYI
PBYI
Q4 25
$13.2M
$14.4M
Q3 25
$-44.8M
$9.7M
Q2 25
$6.4M
$14.1M
Q1 25
$9.9M
$3.6M
Q4 24
$21.7M
$15.6M
Q3 24
$-18.0M
$11.0M
Q2 24
$18.1M
$1.0M
Q1 24
$16.7M
$11.2M
Free Cash Flow
NODK
NODK
PBYI
PBYI
Q4 25
$14.4M
Q3 25
$-44.8M
$9.7M
Q2 25
$6.2M
$14.1M
Q1 25
$9.9M
$3.6M
Q4 24
$21.5M
$15.6M
Q3 24
$-18.1M
$11.0M
Q2 24
$17.5M
$1.0M
Q1 24
$16.6M
FCF Margin
NODK
NODK
PBYI
PBYI
Q4 25
19.1%
Q3 25
-58.6%
17.7%
Q2 25
8.2%
26.8%
Q1 25
13.8%
7.7%
Q4 24
29.1%
26.4%
Q3 24
-20.4%
13.7%
Q2 24
20.0%
2.1%
Q1 24
22.3%
Capex Intensity
NODK
NODK
PBYI
PBYI
Q4 25
0.0%
0.0%
Q3 25
0.0%
0.0%
Q2 25
0.2%
0.0%
Q1 25
0.0%
0.1%
Q4 24
0.3%
0.0%
Q3 24
0.2%
0.0%
Q2 24
0.7%
0.0%
Q1 24
0.1%
0.0%
Cash Conversion
NODK
NODK
PBYI
PBYI
Q4 25
Q3 25
1.10×
Q2 25
2.41×
Q1 25
1.53×
1.21×
Q4 24
2.21×
Q3 24
0.54×
Q2 24
Q1 24
2.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons